手术上用无门替换大动脉门的临床中期结果
Soonchang Hong1, Jung-Woo Son2, Yungjin Yoon1
1Department of Cardiothoracic Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.
Journal of chest surgery
|March 26, 2024
概括
使用Perceval生物假体进行无置换的大动脉,对于患有大动脉狭窄症的高风险患者是安全有效的. 这种程序证明了优秀的长期生存和有利的血液动力学结果.
科学领域:
- 心血管外科心血管外科
- 医疗器械 医疗器械
- 心脏门疾病 心脏门疾病
背景情况:
- 无门的大动脉提供了减少手术时间的潜力,使手术风险增加的患者受益.
- 大动脉狭窄是一种需要干预的严重疾病,通常发生在老年人或高危人群中.
研究的目的:
- 评估Perceval无大动脉生物假体在接受大动脉置换手术 (AVR) 的患者的安全性和有效性.
- 用无门治疗的严重大动脉狭窄症患者队列中评估临床和心声学结果.
主要方法:
- 一个临床数据库的回顾性分析,包括113名患有症状严重的大动脉狭窄的患者,他们接受了无生物假体的外科AVR手术.
- 2015年8月至2020年12月期间收集的患者数据,平均随访时间超过51个月.
- 胸外心声学用于监测射出分数 (EF),左心室质量指数 (LVMI) 和平均压力梯度 (MPG) 的变化.
主要成果:
- 低住院死亡率 (2.6%) 和并发症率,包括永久心脏起器植入 (2.6%).
- 短时间的重症监护病房 (1天) 和住院 (12天) 的中位数.
- 优秀的5年生存率 (95.9%) 显著改善EF和减少LVMI和MPG术后. 没有观察到结构的恶化或显著的对膜泄漏.
结论:
- 无动脉植入是手术AVR的安全和可行的选择,特别是在老年高风险患者中.
- 珀塞瓦尔生物假体带来了有利的血液动力学改善和持续的门功能,没有结构性恶化或显著的泄漏.
相关概念视频
Mitral Valve Prolapse I: Introduction
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...


